Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. Fluvoxamine is FDA approved for treatment of obsessive-compulsive disorder in children ≥8 years of age. Extended-release capsules not FDA approved for use in children. May worsen psychosis in some patients or precipitate shift to mania or hypomania in bipolar disorder. Fluvoxamine not FDA approved for treatment of bipolar depression. Increased risk of bleeding events, particularly if used concomitantly with aspirin, NSAIDs, warfarin or other anticoagulants. Has low potential to impair cognitive or motor performance. Use with or without concomitant antipsychotic therapy associated rarely with neuroleptic malignant syndrome (risk may be increased in Parkinson’s disease or Lewy body dementia). May cause or exacerbate sexual dysfunction. SIADH, or hyponatremia reported rarely (predominately in the elderly). Use with caution in the following conditions: cardiovascular disease, hepatic impairment (decreased clearance and increased plasma concentrations), or previous seizure disorder or condition predisposing to seizures such as brain damage or alcoholism. Use caution with concurrent use of drugs which lower the seizure threshold. Fluvoxamine may significantly increase alosetron concentrations (concurrent use contraindicated). Use caution with concomitant use of NSAIDs, ASA, or other drugs which affect coagulation (risk of bleeding may be potentiated). Use caution with concomitant use of CNS depressants. Potential for severe reaction when used with MAOIs. Serotonin syndrome might occur (avoid use of serotonin precursors). Concurrent use of fluvoxamine with thioridazine or pimozide contraindicated (potential for QTc prolongation and arrhythmia). Concomitant use with tizanidine contraindicated (may cause significant decrease in blood pressure and increase in drowsiness). Use caution in elderly patients (risk of hyponatremia and other adverse events may be increased). Fluvoxamine levels may be lower in patients who smoke. May increase risks associated with electroconvulsive therapy. Withdrawal syndrome is possible.